RQ Bio welcomes positive CHMP opinion on Kavigale for prevention of COVID-19 in immunocompromised individuals
09 janv. 2025 05h00 HE
|
RQ Biotechnology
RQ Bio welcomes positive CHMP opinion on Kavigale for prevention of COVID-19 in immunocompromised individuals
H1 Welcomes Former FDA Commissioner to Board of Directors, Acquires Ribbon Health, and Unveils 2025 Product Roadmap
08 janv. 2025 09h00 HE
|
H1
NEW YORK, Jan. 08, 2025 (GLOBE NEWSWIRE) -- H1, on a mission to connect the world with the right doctors, today announced several key milestones: H1 is strengthening its leadership team with the...
Araris Biotech AG Announces Research Collaboration and Option to License Agreement with Chugai Pharmaceutical Co. to Develop Next-Generation ADCs Using Araris' AraLinQ™ technology
08 janv. 2025 08h00 HE
|
Araris Biotech
Araris will use proprietary AraLinQ™ linker-conjugation platform to generate novel ADCs using antibodies against targets provided by ChugaiAraris to receive an upfront fee and milestone payments...
Galera Therapeutics completes acquisition of Nova Pharmaceuticals
31 déc. 2024 07h00 HE
|
Galera Therapeutics
Galera’s development strategy shifts from toxicity reduction to anti-cancer therapeutics, with three trials in patients with highly resistant subsets of advanced breast cancer. Lead program is...
KFSHRC Inaugurates MENA’s Most Advanced Hematology Diagnostics Laboratory
19 déc. 2024 08h47 HE
|
King Faisal Specialist Hospital & Research Centre
KFSHRC Inaugurates MENA’s Most Advanced Hematology Diagnostics Laboratory
Olympia Pharmaceuticals Announces the Launch of Sister Brand, Wesley Pharmaceuticals, in Honor of Beloved Employee
18 déc. 2024 10h05 HE
|
Olympia Pharmaceuticals
ORLANDO, Fla., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Olympia Pharmaceuticals, a leading innovator in the pharmaceutical industry, is proud to announce the launch of its new sister brand: Wesley...
Silexion Therapeutics collaborates with Evonik on advanced siRNA Formulation Development
17 déc. 2024 06h30 HE
|
Silexion Therapeutics Corp
Cayman Islands, December 17, 2024 – Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven...
[Latest] Global Dry Eye Syndrome Treatment Market Size/Share Worth USD 12,281.4 Million by 2033 at a 7.1% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
11 déc. 2024 12h30 HE
|
Custom Market Insights
Austin, TX, USA, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Dry Eye Syndrome Treatment Market Size, Trends and Insights By Type (Evaporative...
Inflation Reduction Act Likely to Shape Specialty Prescribing Decisions in 2025, According to Spherix Global Insights
10 déc. 2024 09h59 HE
|
Spherix Global Insights
EXTON, PA, Dec. 10, 2024 (GLOBE NEWSWIRE) -- In 2022, the U.S. Congress enacted the Inflation Reduction Act (IRA), a landmark piece of legislation aimed at addressing various national priorities,...
Silexion Therapeutics Appoints Renowned Cancer Therapeutics Expert Prof. Amnon Peled to Board of Directors
10 déc. 2024 08h30 HE
|
Silexion Therapeutics Corp
Cayman Islands, December 10, 2024 – Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven...